P glycoprotein in human immunodeficiency virus type 1 infection and therapy.
作者信息
Sankatsing Sanjay U C, Beijnen Jos H, Schinkel Alfred H, Lange Joep M A, Prins Jan M
机构信息
Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Center, University of Amsterdam, The Netherlands.
出版信息
Antimicrob Agents Chemother. 2004 Apr;48(4):1073-81. doi: 10.1128/AAC.48.4.1073-1081.2004.
Abstract
摘要
相似文献
1
P glycoprotein in human immunodeficiency virus type 1 infection and therapy.1型人类免疫缺陷病毒感染与治疗中的P糖蛋白
Antimicrob Agents Chemother. 2004 Apr;48(4):1073-81. doi: 10.1128/AAC.48.4.1073-1081.2004.
2
Basic pharmacological interactions and how they may impact on one another.
J Acquir Immune Defic Syndr. 2005 Mar;38 Suppl 1:S22-3. doi: 10.1097/01.qai.0000167034.71643.eb.
3
Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors.P-糖蛋白对HIV蛋白酶抑制剂药理学及临床应用的意义
AIDS. 2000 Feb 18;14(3):237-42. doi: 10.1097/00002030-200002180-00005.
4
Potential Tools for Eradicating HIV Reservoirs in the Brain: Development of Trojan Horse Prodrugs for the Inhibition of P-Glycoprotein with Anti-HIV-1 Activity.用于清除大脑中 HIV 储存库的潜在工具：具有抗 HIV-1 活性的 P-糖蛋白抑制作用的特洛伊木马前药的开发。
J Med Chem. 2020 Mar 12;63(5):2131-2138. doi: 10.1021/acs.jmedchem.9b00779. Epub 2019 Sep 20.
5
Role of human CYP3A and P-glycoprotein on the absorption of drugs.人细胞色素P450 3A酶和P-糖蛋白在药物吸收中的作用。
Eur J Pharm Sci. 2000 Nov;12(1):1. doi: 10.1016/s0928-0987(00)00140-8.
6
Cellular factors involved in the induction of resistance of HIV to antiretroviral agents.
Int J Antimicrob Agents. 2000 Nov;16(3):353-6. doi: 10.1016/s0924-8579(00)00264-8.
7
P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.P-糖蛋白和细胞色素 P450 3A 共同作用限制紫杉醇的口服生物利用度。
Int J Cancer. 2013 May 15;132(10):2439-47. doi: 10.1002/ijc.27912. Epub 2012 Nov 14.
8
HIV-1 Alters Intestinal Expression of Drug Transporters and Metabolic Enzymes: Implications for Antiretroviral Drug Disposition.HIV-1改变药物转运体和代谢酶的肠道表达：对抗逆转录病毒药物处置的影响。
Antimicrob Agents Chemother. 2016 Apr 22;60(5):2771-81. doi: 10.1128/AAC.02278-15. Print 2016 May.
9
P-Glycoprotein in clinical cardiology.临床心脏病学中的P-糖蛋白
Circulation. 1999 Feb 2;99(4):472-4. doi: 10.1161/01.cir.99.4.472.
10
Contributions of CYP3A4, P-glycoprotein, and serum protein binding to the intestinal first-pass extraction of saquinavir.细胞色素P450 3A4、P-糖蛋白及血清蛋白结合对沙奎那韦肠道首过提取率的影响
J Pharmacol Exp Ther. 2004 Mar;308(3):941-8. doi: 10.1124/jpet.103.056390. Epub 2004 Jan 8.
引用本文的文献
1
Exploring bat-inspired cyclic tryptophan diketopiperazines as ABCB1 Inhibitors.探索受蝙蝠启发的环状色氨酸二酮哌嗪作为ABCB1抑制剂。
Commun Chem. 2024 Jul 13;7(1):158. doi: 10.1038/s42004-024-01225-z.
2
In vitro and in silico evaluation of antiretrovirals against SARS-CoV-2: A drug repurposing approach.抗逆转录病毒药物针对严重急性呼吸综合征冠状病毒2的体外和计算机模拟评估：一种药物重新利用方法。
AIMS Microbiol. 2023 Jan 16;9(1):20-40. doi: 10.3934/microbiol.2023002. eCollection 2023.
3
The Role of Pannexin-1 Channels in HIV and NeuroHIV Pathogenesis.缝隙连接蛋白 1 通道在人类免疫缺陷病毒和神经人类免疫缺陷病毒发病机制中的作用。
Cells. 2022 Jul 20;11(14):2245. doi: 10.3390/cells11142245.
4
Development of a population pharmacokinetic/pharmacodynamic model for various oral paclitaxel formulations co-administered with ritonavir and thrombospondin-1 based on data from early phase clinical studies.基于早期临床研究数据，开发了一种用于联合利托那韦和血小板反应蛋白-1的各种口服紫杉醇制剂的群体药代动力学/药效学模型。
Cancer Chemother Pharmacol. 2022 Jul;90(1):71-82. doi: 10.1007/s00280-022-04445-z. Epub 2022 Jul 7.
5
Effect of efavirenz-based ART on the pharmacokinetics of rifampicin and its primary metabolite in patients coinfected with TB and HIV.依非韦伦为基础的抗逆转录病毒治疗对合并结核分枝杆菌和人类免疫缺陷病毒感染患者利福平及其主要代谢物药代动力学的影响。
J Antimicrob Chemother. 2021 Oct 11;76(11):2950-2957. doi: 10.1093/jac/dkab258.
6
A comparative analysis of SARS-CoV-2 antivirals characterizes 3CL inhibitor PF-00835231 as a potential new treatment for COVID-19.一项针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）抗病毒药物的比较分析表明，3CL蛋白酶抑制剂PF-00835231是治疗新型冠状病毒肺炎（COVID-19）的一种潜在新疗法。
J Virol. 2021 Mar 10;95(7). doi: 10.1128/JVI.01819-20. Epub 2021 Feb 23.
7
A comparative analysis of SARS-CoV-2 antivirals in human airway models characterizes 3CL inhibitor PF-00835231 as a potential new treatment for COVID-19.在人类气道模型中对SARS-CoV-2抗病毒药物进行的比较分析表明，3CL抑制剂PF-00835231是一种治疗COVID-19的潜在新疗法。
bioRxiv. 2021 Feb 19:2020.08.28.272880. doi: 10.1101/2020.08.28.272880.
8
The pharmacokinetic properties of HIV-1 protease inhibitors: A computational perspective on herbal phytochemicals.HIV-1蛋白酶抑制剂的药代动力学特性：关于草药植物化学成分的计算视角。
Heliyon. 2019 Nov 1;5(10):e02565. doi: 10.1016/j.heliyon.2019.e02565. eCollection 2019 Oct.
9
Risk Factors and Pathogenesis of HIV-Associated Neurocognitive Disorder: The Role of Host Genetics.HIV 相关神经认知障碍的风险因素和发病机制：宿主遗传学的作用。
Int J Mol Sci. 2018 Nov 14;19(11):3594. doi: 10.3390/ijms19113594.
10
Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat .利福平与达芦那韦-利托那韦或达芦那韦-考比司他的相互作用。
Antimicrob Agents Chemother. 2017 Apr 24;61(5). doi: 10.1128/AAC.01776-16. Print 2017 May.
本文引用的文献
1
Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein.
AIDS. 2003 May 2;17(7):1092-4. doi: 10.1097/01.aids.0000060380.78202.b5.
2
Effects of nelfinavir and its M8 metabolite on lymphocyte P-glycoprotein activity during antiretroviral therapy.
Clin Pharmacol Ther. 2003 Jan;73(1):78-86. doi: 10.1067/mcp.2003.11.
3
Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the pharmacokinetic properties of saquinavir coadministered with ritonavir.评估定向P-糖蛋白抑制作用以改善与利托那韦合用的沙奎那韦药代动力学特性的安全性和有效性。
J Pharmacol Exp Ther. 2003 Feb;304(2):596-602. doi: 10.1124/jpet.102.044388.
4
Intracellular concentration of protease inhibitors in HIV-1-infected patients: correlation with MDR-1 gene expression and low dose of ritonavir.HIV-1感染患者细胞内蛋白酶抑制剂浓度：与多药耐药基因1（MDR-1）表达及低剂量利托那韦的相关性
HIV Clin Trials. 2002 Nov-Dec;3(6):493-501. doi: 10.1310/0873-bvdp-akay-445u.
5
Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors.乳腺癌耐药蛋白（BCRP/ABCG2）可诱导细胞对HIV-1核苷类逆转录酶抑制剂产生耐药性。
Mol Pharmacol. 2003 Jan;63(1):65-72. doi: 10.1124/mol.63.1.65.
6
Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs.多药耐药蛋白2（MRP2）可转运HIV蛋白酶抑制剂，且其他药物可增强其转运作用。
AIDS. 2002 Nov 22;16(17):2295-301. doi: 10.1097/00002030-200211220-00009.
7
MDR1 genotype-related pharmacokinetics and pharmacodynamics.多药耐药基因1（MDR1）基因型相关的药代动力学和药效学
Biol Pharm Bull. 2002 Nov;25(11):1391-400. doi: 10.1248/bpb.25.1391.
8
Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2).关于沙奎那韦由多药耐药相关蛋白（MRP1）和胆小管多特异性有机阴离子转运体（MRP2）转运的直接证据。
Antimicrob Agents Chemother. 2002 Nov;46(11):3456-62. doi: 10.1128/AAC.46.11.3456-3462.2002.
9
Expression and localization of P-glycoprotein in human heart: effects of cardiomyopathy.P-糖蛋白在人心脏中的表达与定位：心肌病的影响
J Histochem Cytochem. 2002 Oct;50(10):1351-6. doi: 10.1177/002215540205001008.
10
P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals.P-糖蛋白和多药耐药相关蛋白1的表达以及HIV感染者中利托那韦和沙奎那韦蓄积的减少
J Antimicrob Chemother. 2002 Oct;50(4):583-8. doi: 10.1093/jac/dkf161.
Zotero 插件